

Supplementary Table S1. Therapeutic profiles of CCRT followed by durvalumab consolidation

<b>Chemoradiotherapy phase</b>		<b>n, (%)</b>
<b>Radiotherapy</b>	Median total radiation, (range)	60 Gy (45-60)
	Median total fraction, (range)	30 Fr (15-30)
<b>Chemotherapy regimen</b>	Weekly CBDCA+PTX	12 (40)
	Low dose CBDCA	7 (23.3)
	CDDP+DTX	3 (10)
	CBDCA+PTX	3 (10)
	CDDP+S-1	3 (10)
	CDDP+PEM	1 (3.3)
	CDDP+ETP	1 (3.3)
<b>Durvalumab consolidation phase</b>		
<b>Completion or withdrawal of durvalumab administration</b>	Completion of durvalumab	10 (33.3)
	Discontinuation due to AEs	3 (10)
	Discontinuation due to PD	16 (19.7)
	Others	1 (3.3)

CCRT, concurrent chemoradiotherapy; Gy, gray; Fr, fractions; CBDCA, carboplatin; PTX, paclitaxel; CDDP, cisplatin; DTX, docetaxel; PEM, pemetrexed; ETP, etoposide; AE, adverse event; PD, progressive disease.